Table 3.

Response to upadacitinib therapy evaluated through the achievement of additional treatment goals proposed by De Bruin Weller et al. [19]

Therapeutic goals	Week 4	Week 16
Patients achieving absolute EASI score ≤ 7, n (%)		38/39 (97.4)
Patients achieving the reduction of at least 3 points in the absolute itch-NRS score, n (%)	24/26 (92.3)
Patients achieving the absolute itch-NRS score ≤ 4, n (%)		37/39 (94.9)
Patients achieving the reduction of absolute DLQI score of at least 4 points, n (%)	24/26 (92.3)
Patients achieving the absolute DLQI score ≤ 5, n (%)		38/39 (97.4)
Patients achieving the reduction of absolute POEM score of at least 4 points, n (%)	23/26 (88.5)
Patients achieving the absolute POEM score ≤ 7, n (%)		36/39 (92.3)

DLQI dermatology life quality index, EASI eczema area severity index, NRS numeric rating scale, POEM patient-oriented eczema measure